Apomorphine for Women's Desire: What the Research Actually Shows

what apomorphine is and how it works

Apomorphine is a molecule that's been in medicine for over a century. At low doses, it acts on dopamine receptors in the brain: specifically the pathways involved in motivation, reward, and arousal. The result, in studies, is an increase in arousal response. Not a change in hormone levels, but a direct signal to the brain systems involved in desire.

This brain-pathway approach puts it in the same conceptual category as PT-141 (bremelanotide), the FDA-approved peptide for female desire. Both work centrally rather than on blood flow or hormones. The difference is the specific receptor: apomorphine targets dopamine receptors; PT-141 targets melanocortin receptors.

what the research shows for women

The evidence is real but limited. Several small trials in the early 2000s tested sublingual apomorphine (dissolved under the tongue) in women with arousal difficulties and found meaningful improvements in genital arousal response compared to placebo.

The results attracted genuine attention. But the studies were small, the effects were modest, and tolerability was a consistent problem: nausea and dizziness were reported frequently enough that they limited practical use.

Apomorphine didn't go on to larger Phase 3 trials for female desire. It had a separate chapter in male erectile dysfunction, where it was briefly approved in the UK and some European countries, then withdrawn after better-tolerated options became available. When that chapter closed, further commercial development for women's desire largely stopped with it.

why it's not the standard option for female HSDD

Apomorphine has no FDA-approved indication for hypoactive sexual desire disorder (HSDD) or female arousal disorder. There are no large Phase 3 trials in women, no approved prescribing pathway in the US for this use, and most physicians have no familiarity with it in this context.

The tolerability concern is the practical ceiling. A molecule that produces meaningful improvement for some women but causes frequent nausea is a difficult clinical proposition, especially when alternatives exist. The early evidence showed promise; the path to approval simply was never completed.

what is available for women in the US today

The option that completed large Phase 3 trials for female desire, earned FDA approval, and is available through US telehealth today is PT-141 (bremelanotide). Like apomorphine, it works centrally on a brain pathway tied to arousal. The RECONNECT trials tested it in thousands of premenopausal women with HSDD and produced results strong enough for FDA approval in 2019, under the brand name Vyleesi. Compounded bremelanotide is the same active molecule at the same dose, prescribed through licensed US physicians and filled by licensed US pharmacies.

PT-141 comes in two forms: an at-home injection taken about 45 minutes before intimacy, with a longer, more forgiving timing window; and a nasal spray used before intimacy on the timing your prescriber sets. Both are used as needed. Neither form is on a daily schedule.

The PT-141 for women page covers how it works, what to expect from each form, and how the online visit works. A licensed US physician reviews your intake before anything is prescribed. You're charged only after approval. The intake takes about 2 minutes.

If your low desire has a different cause (hormonal changes, a medication side effect, stress), the path starts somewhere else. Reasons for low sex drive in women is a useful place to start narrowing it down.

the short version

Apomorphine has legitimate research behind it for female arousal. The science showed real effects. The tolerability issues, combined with a lack of Phase 3 trials and FDA approval, mean it's not the option available to most women in the US today.

PT-141 is the central-acting option that completed that path. If you're considering your choices for low desire, that's where the approved, prescribable science currently sits.